OnabotulinumtoxinA for Chronic Migraine: Safety and Tolerability of the Effective Treatment Paradigm in the PREEMPT Clinical Program

被引：0
|
作者：
Aurora, S. K. [1 ]
Dodick, D. W. [2 ]
Blumenfeld, A. [3 ]
DeGryse, R. E. [4 ]
Turkel, C. C. [4 ]
机构：
[1] Swedish Neurosci Inst, Seattle, WA USA
[2] Mayo Clin, Phoenix, AZ USA
[3] Neurol Ctr, Encinitas, CA USA
[4] Allergan, Irvine, CA USA
来源：
HEADACHE | 2010年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S14 / S15
页数：2
相关论文
共 50 条
  • [1] OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
    Aurora, S. K.
    Dodick, D. W.
    Diener, H. -C.
    DeGryse, R. E.
    Turkel, C. C.
    Lipton, R. B.
    Silberstein, S. D.
    ACTA NEUROLOGICA SCANDINAVICA, 2014, 129 (01): : 61 - 70
  • [2] Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program
    Blumenfeld, Andrew
    Silberstein, Stephen D.
    Dodick, David W.
    Aurora, Sheena K.
    Turkel, Catherine C.
    Binder, William J.
    HEADACHE, 2010, 50 (09): : 1406 - 1418
  • [3] OnabotulinumtoxinA for Chronic Migraine: Efficacy and Tolerability in Patients Who Received All 5 Treatment Cycles in the PREEMPT Clinical Program
    Aurora, S. K.
    Dodick, D. W.
    DeGryse, R. E.
    Turkel, C. C.
    HEADACHE, 2011, 51 : 61 - 61
  • [4] OnabotulinumtoxinA for Chronic Migraine: Safety and Efficacy of Fixed-Site, Fixed-Dose Injection Paradigm in PREEMPT Clinical Program
    Diener, Hans-Christoph
    Dodick, David W.
    DeGryse, Ronald E.
    Turkel, Catherine C.
    NEUROLOGY, 2011, 76 (09) : A267 - A267
  • [5] OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm
    Isabel Pedraza, Maria
    de la Cruz, Carolina
    Ruiz, Marina
    Lopez-Mesonero, Luis
    Martinez, Elena
    de Lera, Mercedes
    Luis Guerrero, Angel
    SPRINGERPLUS, 2015, 4
  • [6] OnabotulinumtoxinA for Chronic Migraine: PREEMPT Trials Establish a Safe and Effective Dose and Injection Paradigm
    Blumenfeld, Andrew M.
    Silberstein, Stephen D.
    Dodick, David W.
    Aurora, Sheena K.
    Turkel, Catherine C.
    Binder, William J.
    NEUROLOGY, 2010, 74 (09) : A573 - A573
  • [7] OnabotulinumtoxinA for chronic migraine: PREEMPT trials establish a safe and effective dose and injection paradigm
    Blumenfeld, A. M.
    Silberstein, S. D.
    Dodick, D. W.
    Aurora, S. K.
    Turkel, C. C.
    Binder, W. J.
    TOXICON, 2013, 68 : 106 - 107
  • [8] OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program
    Aurora, Sheena K.
    Winner, Paul
    Freeman, Marshall C.
    Spierings, Egilius L.
    Heiring, Jessica O.
    DeGryse, Ronald E.
    VanDenburgh, Amanda M.
    Nolan, Marissa E.
    Turkel, Catherine C.
    HEADACHE, 2011, 51 (09): : 1358 - 1373
  • [9] OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT
    Aurora, S. K.
    Dodick, D. W.
    DeGryse, R. E.
    Turkel, C. C.
    JOURNAL OF HEADACHE AND PAIN, 2013, 14
  • [10] OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT
    SK Aurora
    DW Dodick
    RE DeGryse
    CC Turkel
    The Journal of Headache and Pain, 2013, 14
12345